A 1-Year Study On The Effects Of CP-945,598 For The Treatment Of Obesity In Overweight Type 2 Diabetic Patients
NCT ID: NCT00391196
Last Updated: 2012-11-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
975 participants
INTERVENTIONAL
2006-11-30
2009-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo
Placebo
Subjects receive placebo plus non-pharmacological weight loss program.
CP-945,598
CP-945,598
Subjects receive CP-945,598 plus non-pharmacological weight loss program.
CP-945,598 Treatment B
Subjects receive CP-945,598 plus non-pharmacological weight loss program.
CP-945,598 Treatment B
Subjects receive CP-945,598 plus non-pharmacological weight loss program.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
Subjects receive placebo plus non-pharmacological weight loss program.
CP-945,598
Subjects receive CP-945,598 plus non-pharmacological weight loss program.
CP-945,598 Treatment B
Subjects receive CP-945,598 plus non-pharmacological weight loss program.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subjects must have type 2 diabetes mellitus
Exclusion Criteria
* Serious or unstable current or past medical conditions
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Birmingham, Alabama, United States
Pfizer Investigational Site
Huntsville, Alabama, United States
Pfizer Investigational Site
Mobile, Alabama, United States
Pfizer Investigational Site
Chandler, Arizona, United States
Pfizer Investigational Site
Mesa, Arizona, United States
Pfizer Investigational Site
Phoenix, Arizona, United States
Pfizer Investigational Site
Fresno, California, United States
Pfizer Investigational Site
Palm Springs, California, United States
Pfizer Investigational Site
Tustin, California, United States
Pfizer Investigational Site
Walnut Creek, California, United States
Pfizer Investigational Site
New Britain, Connecticut, United States
Pfizer Investigational Site
Washington D.C., District of Columbia, United States
Pfizer Investigational Site
Orlando, Florida, United States
Pfizer Investigational Site
West Palm Beach, Florida, United States
Pfizer Investigational Site
Honolulu, Hawaii, United States
Pfizer Investigational Site
Gurnee, Illinois, United States
Pfizer Investigational Site
Madisonville, Kentucky, United States
Pfizer Investigational Site
Baton Rouge, Louisiana, United States
Pfizer Investigational Site
Metairie, Louisiana, United States
Pfizer Investigational Site
Auburn, Maine, United States
Pfizer Investigational Site
Scarborough, Maine, United States
Pfizer Investigational Site
Baltimore, Maryland, United States
Pfizer Investigational Site
Bay City, Michigan, United States
Pfizer Investigational Site
Troy, Michigan, United States
Pfizer Investigational Site
Edina, Minnesota, United States
Pfizer Investigational Site
Jefferson City, Missouri, United States
Pfizer Investigational Site
Albuquerque, New Mexico, United States
Pfizer Investigational Site
Buffalo, New York, United States
Pfizer Investigational Site
New York, New York, United States
Pfizer Investigational Site
Greenville, North Carolina, United States
Pfizer Investigational Site
Beaver, Pennsylvania, United States
Pfizer Investigational Site
Cumberland, Rhode Island, United States
Pfizer Investigational Site
Pawtucket, Rhode Island, United States
Pfizer Investigational Site
Greer, South Carolina, United States
Pfizer Investigational Site
Bristol, Tennessee, United States
Pfizer Investigational Site
Nashville, Tennessee, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
Dallas, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
San Antonio, Texas, United States
Pfizer Investigational Site
Renton, Washington, United States
Pfizer Investigational Site
Morgantown, West Virginia, United States
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Buenos Aires, , Argentina
Pfizer Investigational Site
Garran, Australian Capital Territory, Australia
Pfizer Investigational Site
Wollongong, New South Wales, Australia
Pfizer Investigational Site
Adelaide, South Australia, Australia
Pfizer Investigational Site
Box Hill, Victoria, Australia
Pfizer Investigational Site
Nedlands, Western Australia, Australia
Pfizer Investigational Site
Curitiba, Paraná, Brazil
Pfizer Investigational Site
Porto Alegre, Rio Grande do Sul, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
São Paulo, São Paulo, Brazil
Pfizer Investigational Site
Red Deer, Alberta, Canada
Pfizer Investigational Site
Coquitlam, British Columbia, Canada
Pfizer Investigational Site
Winnipeg, Manitoba, Canada
Pfizer Investigational Site
Thornhill, Ontario, Canada
Pfizer Investigational Site
Charlottetown, Prince Edward Island, Canada
Pfizer Investigational Site
L'Ancienne-Lorette, Quebec, Canada
Pfizer Investigational Site
Saint-Marc-des-Carrieres, Quebec, Canada
Pfizer Investigational Site
Břeclav, , Czechia
Pfizer Investigational Site
České Budějovice, , Czechia
Pfizer Investigational Site
Olomouc, , Czechia
Pfizer Investigational Site
Prague, , Czechia
Pfizer Investigational Site
Praha 4 - Krc, , Czechia
Pfizer Investigational Site
Berlin, , Germany
Pfizer Investigational Site
Dresden, , Germany
Pfizer Investigational Site
Düsseldorf, , Germany
Pfizer Investigational Site
Hamburg, , Germany
Pfizer Investigational Site
Leipzig, , Germany
Pfizer Investigational Site
Mittweida, , Germany
Pfizer Investigational Site
Tampico, Cd. Madero, Mexico
Pfizer Investigational Site
Guadalajara, Jalisco, Mexico
Pfizer Investigational Site
Mexico City, Mexico City, Mexico
Pfizer Investigational Site
Monterrey, Nuevo León, Mexico
Pfizer Investigational Site
Bratislava, Slovakia, Slovakia
Pfizer Investigational Site
Ľubochňa, Slovakia, Slovakia
Pfizer Investigational Site
Nitra, Slovakia, Slovakia
Pfizer Investigational Site
Banská Bystrica, , Slovakia
Pfizer Investigational Site
Gothenburg, , Sweden
Pfizer Investigational Site
Huddinge, , Sweden
Pfizer Investigational Site
Edinburgh, Lothian, United Kingdom
Pfizer Investigational Site
Bath, Somerset, United Kingdom
Pfizer Investigational Site
Coventry, , United Kingdom
Pfizer Investigational Site
Dumfries, , United Kingdom
Pfizer Investigational Site
Dundee, , United Kingdom
Pfizer Investigational Site
Luton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
A5351022
Identifier Type: -
Identifier Source: org_study_id